Top

Published in:

01-04-2023 | Lymphoma | Case Report

Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome

Authors: Christopher N. Nguyen, Swaminathan P. Iyer, Madeleine Duvic, Prajak J. Barde, Ajit Nair, Kasi Viswanath Routhu, Auris O. Huen

Published in: Investigational New Drugs | Issue 2/2023

Summary

Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common subtypes of cutaneous T cell lymphomas (CTCL). Advanced-stage MF/SS have poor prognoses and may be refractory to multiple systemic treatments. These cases can be difficult to achieve and maintain complete response and there is a need for novel therapeutics. Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway by Tenalisib presents one such emerging drug. We report a relapsed/refractory SS patient achieving complete remission using the combination of Tenalisib and Romidepsin and subsequently maintaining long-duration CR with Tenalisib monotherapy.

Hristov AC, Tejasvi T, A Wilcox R (2021) Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 96(10):1313–1328. https://doi.org/10.1002/ajh.26299

Alpdogan O, Kartan S, Johnson W, Sokol K, Porcu P (2019) Systemic therapy of cutaneous T-cell lymphoma (CTCL). Chin Clin Oncol 8(1):10. https://doi.org/10.21037/cco.2019.01.02CrossRefPubMed

Lampson BL, Brown JR (2017) PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 26(11):1267–1279. https://doi.org/10.1080/13543784.2017.1384815CrossRefPubMedPubMedCentral

Huen A, Haverkos BM, Zain J et al (2020) Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers (Basel) 12(8):2293. Published 2020 Aug 15. https://doi.org/10.3390/cancers12082293

Horwitz SM, Koch R, Porcu P et al (2018) Activity of the PI3K-δ, γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 131(8):888–898. https://doi.org/10.1182/blood-2017-08-802470CrossRefPubMedPubMedCentral

Safety and Efficacy of Tenalisib (RP6530) in Combination with Romidepsin in Patients with Relapsed/Refractory T-cell Lymphoma. Available online: https://clinicaltrials.gov/ct2/show/NCT03770000. Accessed 30 Apr 2022

Compassionate Use Study of Tenalisib (RP6530). Available online: https://clinicaltrials.gov/ct2/show/NCT03711604. Accessed 30 Apr 2022

Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M (2015) Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. Clin Lymphoma Myeloma Leuk 15(5):e83–e93. https://doi.org/10.1016/j.clml.2014.09.013CrossRefPubMed

Kim YH, Bagot M, Pinter-Brown L et al (2018) Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial [published correction appears in Lancet Oncol. 2018 Nov;19(11):e581]. Lancet Oncol 19(9):1192–1204. https://doi.org/10.1016/S1470-2045(18)30379-6

10.

Beygi S, Duran GE, Fernandez-Pol S, Rook AH, Kim YH, Khodadoust MS (2022) Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma [published online ahead of print, 2022 Apr 18]. Blood blood.2021014468. https://doi.org/10.1182/blood.2021014468

11.

Hughes CF, Khot A, McCormack C et al (2015) Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 125(1):71–81. https://doi.org/10.1182/blood-2014-07-588236CrossRefPubMed

12.

Talpur R, Thompson A, Gangar P, Duvic M (2014) Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 14(4):297–304. https://doi.org/10.1016/j.clml.2014.01.010CrossRefPubMed

13.

Carlo-Stella C, Delarue R, Scarfo L et al (2020) A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study. Clin Lymphoma Myeloma Leuk 20(2):78–86. https://doi.org/10.1016/j.clml.2019.10.013CrossRefPubMed

14.

Iyer SP, Huen A, Ferreri AJM et al (2018) Pooled safety analysis and efficacy of Tenalisib (RP6530), a PI3K δ/γ inhibitor in patients with relapsed/refractory lymphoid malignancies. Blood 132:2925. https://doi.org/10.1182/blood-2018-99-112757CrossRef

15.

Iyer S, Huen A, Ai W et al (2021) Safety and efficacy of tenalisib given in combination with Romidepsin in patients with relapsed/refractory T-Cell Lymphoma: Final results from a phase I/II open label multi-center study. Blood (ASH Annual Meeting Abstracts)

16.

Kaneda MM, Messer KS, Ralainirina N et al (2016) PI3Kγ is a molecular switch that controls immune suppression. Nature 539(7629):437–442. https://doi.org/10.1038/nature19834

17.

Lewis J, Girardi M, Vakkalanka S, Viswanadha S, Bertoni F (2013) RP6530, a dual PI3Kδ/γ inhibitor, attenutates AKT phosphorylation and induces apoptosis in primary cutaneous T cell lymphoma (CTCL) cells. Blood 22:4418. https://doi.org/10.1182/blood.V122.21.4418.4418CrossRef

Title: Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome
Authors: Christopher N. Nguyen
Swaminathan P. Iyer
Madeleine Duvic
Prajak J. Barde
Ajit Nair
Kasi Viswanath Routhu
Auris O. Huen
Publication date: 01-04-2023
Publisher: Springer US
Keywords: Lymphoma
Sézary Syndrome
Mycosis Fungoides
Published in: Investigational New Drugs / Issue 2/2023
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-022-01315-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 2/2023

Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations

Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group

Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors

Mesenchymal stem cells: a trojan horse to treat glioblastoma

A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies

Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer